Sofosbuvir/Velpatasvir in Chronic Hepatitis C, Compensated and Decompensated Cirrhosis, and Retreatment Settings

@article{takada2026sofosbuvirvelpatasvir,
  title = {{Sofosbuvir/Velpatasvir in Chronic Hepatitis C, Compensated and Decompensated Cirrhosis, and Retreatment Settings}},
  author = {Hitomi Takada and Nobuharu Tamaki and Hironori Ochi and Nami Mori and Keiji Tsuji and Toshifumi Tada and Shinichiro Nakamura and Junichi Toshimori and Naoki Yoshioka and Hirotaka Arai and Hideki Fujii and Chitomi Hasebe and Toshimitsu Murohisa and Eisuke Okamoto and Masahiko Kondo and Hiroyuki Marusawa and Naohito Urawa and Takuto Yoshioka and Hideo Yoshida and Ryoichi Narita and Takehiro Akahane and Atsunori Kusakabe and Michiko Nonogi and Ryosuke Imado and Yasushi Uchida and Takashi Sato and Keisuke Yokohama and Yoshihito Kubotsu and Toru Ishii and Namiki Izumi and Masayuki Kurosaki},
  journal = {Internal Medicine},
  year = {2026},
  month = aug,
  doi = {10.2169/internalmedicine.6497-25},
  url = {https://www.jstage.jst.go.jp/article/internalmedicine/65/16/65_6497-25/_article},
  note = {CC BY-NC-ND},
}

TY  - JOUR
TI  - Sofosbuvir/Velpatasvir in Chronic Hepatitis C, Compensated and Decompensated Cirrhosis, and Retreatment Settings
AU  - Hitomi Takada
AU  - Nobuharu Tamaki
AU  - Hironori Ochi
AU  - Nami Mori
AU  - Keiji Tsuji
AU  - Toshifumi Tada
AU  - Shinichiro Nakamura
AU  - Junichi Toshimori
AU  - Naoki Yoshioka
AU  - Hirotaka Arai
AU  - Hideki Fujii
AU  - Chitomi Hasebe
AU  - Toshimitsu Murohisa
AU  - Eisuke Okamoto
AU  - Masahiko Kondo
AU  - Hiroyuki Marusawa
AU  - Naohito Urawa
AU  - Takuto Yoshioka
AU  - Hideo Yoshida
AU  - Ryoichi Narita
AU  - Takehiro Akahane
AU  - Atsunori Kusakabe
AU  - Michiko Nonogi
AU  - Ryosuke Imado
AU  - Yasushi Uchida
AU  - Takashi Sato
AU  - Keisuke Yokohama
AU  - Yoshihito Kubotsu
AU  - Toru Ishii
AU  - Namiki Izumi
AU  - Masayuki Kurosaki
PY  - 2026
DA  - 2026/08/15
JO  - Internal Medicine
DO  - 10.2169/internalmedicine.6497-25
UR  - https://www.jstage.jst.go.jp/article/internalmedicine/65/16/65_6497-25/_article
AB  - Objective Sofosbuvir/velpatasvir (SOF/VEL) has been approved for various stages of hepatitis C virus (HCV) infection; however, real-world data on Japanese patients remain limited. We evaluated the efficacy of SOF/VEL treatment in Japanese patients with chronic hepatitis, compensated cirrhosis, decompensated cirrhosis, and direct-acting antiviral (DAA) retreatment. Methods This multicenter prospective study enrolled 236 patients treated with SOF/VEL (with ribavirin for retreatment) at 21 Japanese institutions (chronic hepatitis, n=35; compensated cirrhosis, n=43; decompensated cirrhosis, n=134; undergoing DAA retreatment, n=24). The primary outcome was the sustained virologic response (SVR) rate at 24 weeks post-treatment (SVR24). In decompensated cirrhosis, liver function changes were assessed using the modified albumin-bilirubin (ALBI) score. Results The overall SVR24 rate was 97%, with SVR24 achieved in 100% of the patients with chronic hepatitis and compensated cirrhosis, 96% of those with decompensated cirrhosis, and 92% of those undergoing DAA retreatment. In the decompensated cirrhosis group, a significant improvement in the modified ALBI scores was observed from baseline to SVR24, and this improvement was sustained for two years after treatment. The proportion of patients with modified ALBI grades 1 or 2a increased from 5.2% at baseline to 23% at the end of treatment, 31% at SVR12, 35% at SVR24, 37% at 1 year, and 44% at 2 years post-treatment. Conclusion SOF/VEL has demonstrated high efficacy in all stages of hepatitis C, including patients with chronic hepatitis, compensated cirrhosis, decompensated cirrhosis, and prior DAA failure. The ability to achieve high efficacy at any stage of chronic hepatitis C is expected to improve the prognosis for a wide range of patients.
SN  - 1349-7235
SN  - 0918-2918
ER  -